Trimi’s public pricing explanation supplies a detail that many monthly-looking offers leave unclear: its $99 semaglutide figure is an annual-plan equivalent, with $1,188 due upfront for a twelve-month commitment. The month-to-month price is separately listed as $175. These are different purchase models, not interchangeable ways to quote one payment.
The same distinction applies to tirzepatide, advertised at $125 per month on an annual plan billed $1,500 upfront, or $235 month to month. This review keeps that financial clarity alongside the prescription, compounded-product and outcome limitations.
Trimi: monthly equivalents by medicine and term
Advertised US dollars; billing scope shown on every row
Provider-advertised information checked October 7, 2026. Items can have different inclusions or commitments; read each row before comparing. Calculations are labeled.
View the printable chart image
The lower equivalent has a larger first payment
Trimi’s answers page gives both the annual total and the month-to-month figure. At unchanged monthly prices, twelve semaglutide payments would total $2,100 versus $1,188 upfront; twelve tirzepatide payments would total $2,820 versus $1,500 upfront. Those differences describe payment structures, not the suitability of a year-long treatment commitment.
The annual comparison should include the policy for a medical stop, an unused supply and any refund promise. A reader who might need a different medication or another care arrangement should resolve those rules before treating the arithmetic saving as money they will necessarily retain.
Trial references need their original product context
Trimi’s homepage cites branded-medicine study averages while describing compounded preparations. This publication keeps those references separate: the trial describes the studied product, dose and population; it does not measure the performance of Trimi’s supplied preparation or its service quality.
Questions worth answering
What is the most useful detail to verify before choosing Trimi?
Trimi explicitly distinguishes an annual upfront charge from month-to-month pricing for both medicines. Save the selected product name, payment or supply period, and the source or agreement that confirms it. A written record makes later changes easier to identify.
Does this review establish how much weight I would lose?
No. This is a review of public offer information, including its billing and service model. A provider advertisement, testimonial, or trial of a branded medicine does not establish the outcome of an individual order from Trimi.
Sources & chart notes
Source dates are listed with each document. Earlier research and later offer updates are identified separately. Provider pages establish advertised terms. Labels and trial reports describe specific medicines and study populations. Medical review has not been completed.
- Trimi — official offer ↗Provider information ·
- Trimi — billing and treatment answers ↗Provider information ·
- FDA — unapproved GLP-1 drug concerns ↗FDA safety information ·
The annual equivalent is not a monthly charge
Trimi’s answers page states the total upfront amounts and describes no membership, enrollment or shipping fee within those offers. That makes the included-cost presentation relatively concrete. A reader can compare the full commitment rather than assuming the smallest monthly-looking figure is what leaves the account each month.
A year paid upfront also creates a different flexibility question from a month-to-month plan. The published amounts do not by themselves settle every cancellation or unused-term refund circumstance. The renewal guide makes those financial questions visible without assuming the annual offer is always better value.
The price includes a conditional clinical pathway
Trimi describes licensed provider review, pharmacy compounding, supplies and shipping within the price. It names Arora Health as its clinical network and says each prescription is reviewed by a licensed US provider. The actual medication still depends on that professional decision.
The page advertises an automatic refund when its medical team does not approve treatment. That is a specific nonapproval circumstance, distinct from the separate money-back promise connected to weight change. Neither description amounts to a personal eligibility assessment carried out by this publication.
Trial references do not become Trimi outcomes
The homepage names STEP-1, SURMOUNT-1 and SELECT and explicitly says the figures come from active-ingredient trials rather than guaranteeing individual results. That qualification is essential. These are not observed results from a Trimi patient cohort or a study of every compounded prescription it dispenses.
Trimi also states that compounded preparations are not FDA-approved as drugs. A named ingredient study, clinical network and pharmacy process have separate roles. The treatment guide explains why those features do not transfer a branded medicine’s approval to a compounded finished preparation.
The useful comparison is both financial and clinical
Trimi’s strongest public feature is the explicit upfront-versus-monthly distinction. The open question concerns the complete selected agreement, including continuing terms and how any refund promise works. This review did not purchase an annual plan, authenticate a pharmacy or measure a treatment outcome.
The Fridays review follows a four-month membership promotion, while Henry describes longer-plan balance qualifications. The cost guide connects those commitments. It does not treat an annual equivalent as proof of affordability or suitability for every reader.
Focused comparisons for this offer
See Cheapest semaglutide injection plans: offers with the whole bill visible · Cheapest tirzepatide injection plans: offers beyond the lowest monthly number · Best month-to-month injection-plan comparisons: ways to limit upfront commitment · Best annual GLP-1 plan comparisons and monthly alternatives: payment choices · Best GLP-1 programs when switching providers: routes for a clear handoff.
Compare another model
Embody · CareBox · He & She MD · CoreAge Rx
The invoice guide and product-status guide explain the distinctions behind these entries.
Documents used
Original references are retained below. Later observations and their source dates are identified in the dated updates and research notes. Advertising describes an offer; it is not independent verification of treatment outcomes.